Background: There are no biological markers to predict the onset of acute kidney injury (AKI) in patients with acute decompensated heart failure (ADHF). Liver-type fatty acid-binding protein (L-FABP) levels are markedly upregulated in the proximal tubules after renal ischemia. We investigated whether urinary L-FABP is a suitable marker to predict AKI in ADHF patients. Methods: We examined 281 consecutive patients with ADHF. Serum creatinine (Cr) and L-FABP levels were measured at admission and 24 and 48 h after admission. Results: AKI developed in 104 patients (37%). Urinary L-FABP levels at admission were significantly higher in patients with AKI than in those without (33.0 vs. 5.2 μg/g Cr; p < 0.001). Multivariate analysis showed that baseline urinary L-FABP level was an independent predictor of AKI in ADHF patients (odds ratio 1.08, 95% confidence interval 1.05-1.12; p < 0.001). Receiver operating characteristic analysis showed that baseline urinary L-FABP level exhibited 94.2% sensitivity and 87.0% specificity at a cutoff value of 12.5 μg/g Cr. Conclusions: Urinary L-FABP level is useful for predicting the onset of AKI in patients with ADHF. The results of our study could help clinicians diagnose AKI in ADHF patients earlier, leading to possible improvements in the treatment of this group of patients.

Keywords:
Acute kidney injury, Acute decompensated heart failure, Liver-type fatty acid-binding protein
1.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al: Heart disease and stroke statistics - 2015 update: a report from the American Heart Association. Circulation 2015;131:e29-e322.
2.
Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al: Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003;9:13-25.
3.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539.
4.
Yamamoto T, Yamamoto A, Watanabe M, Matsuo T, Yamazaki N, Kataoka M, et al: Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues. Biotechnol Lett 2009;31:1695-1701.
5.
Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, et al: Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165:1243-1255.
6.
Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, et al: Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004;143:23-30.
7.
Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S: NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Adv Med Sci 2009;54:221-224.
8.
Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al: Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-3968.
9.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
10.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
11.
Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B; POSH Investigators: Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006;27:1216-1222.
12.
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
13.
Veerkamp JH, Peeters RA, Maatman RG: Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1991;1081:1-24.
14.
Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, et al: The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-141.
15.
Kociol RD, Greiner MA, Hammill BG, Phatak H, Fonarow GC, Curtis LH, et al: Long-term outcomes of Medicare beneficiaries with worsening renal function during hospitalization for heart failure. Am J Cardiol 2010;105:1786-1793.
16.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure: Definition, outcome measures, animal models, fluid therapy and information technology needs - the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:204-212.
17.
Khwaja A: KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:179-184.
18.
Nakamura T, Sugaya T, Node K, Ueda Y, Koide H: Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis 2006;47:439-444.
19.
Obata Y, Kamijo-Ikemori A, Ichikawa D, Sugaya T, Kimura K, Shibagaki Y, et al: Clinical usefulness of urinary liver-type fatty-acid-binding protein as a perioperative marker of acute kidney injury in patients undergoing endovascular or open-abdominal aortic aneurysm repair. J Anesth 2016;30:89-99.
20.
Sasaki H, Kamijo-Ikemori A, Sugaya T, Yamashita K, Yokoyama T, Koike J, et al: Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract 2009;112:148-156.
21.
Matthys E, Patel Y, Kreisberg J, Stewart JH, Venkatachalam M: Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney Int 1984;26:153-161.
22.
Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, et al: Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007;18:2894-2902.
23.
Noiri E, Doi K, Negishi K, Tanaka T, Hamasaki Y, Fujita T, et al: Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol 2009;296:669-679.
24.
Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, et al: Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Am J Hypertens 2007;20:1195-1201.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.